Ask your doctor if you can drive or operate machines.
Oxicodona/Naloxona Teva contains sodium
This medication contains less than 1 mmol of sodium (23 mg) per tablet, which is essentially “sodium-free”.
Before starting treatment and periodically during treatment, your doctor will discuss with you what you can expect from the use of oxicodona/naloxona, when and for how long you should take it, when to contact your doctor, and when to stop taking it (see also “If you interrupt Oxicodona/Naloxona Teva treatment”).
Oxicodona/Naloxona Teva is a prolonged-release tablet, meaning that the active ingredients are released over a prolonged period of time. Its effect lasts 12 hours.
The prolonged-release tablet can be divided into equal doses, but it should not be chewed or crushed.
Taking chewed or crushed tablets can lead to the absorption of a potentially lethal dose of hydrochloride oxicodona (see section 3 “If you take more Oxicodona/Naloxona Teva than you should”).
Unless your doctor tells you otherwise, the usual dose is:
For pain treatment
Adults
The usual initial dose is 10 mg of hydrochloride oxicodona/5 mg of hydrochloride naloxona in prolonged-release tablets every 12 hours.
Your doctor will decide the dose of Oxicodona/Naloxona Teva you should take per day and how to divide it into morning and night doses. They will also decide if you need to adjust the dose during treatment. Your dose will be adjusted according to your level of pain and individual sensitivity. You should receive the minimum dose necessary to relieve pain. If you have already received treatment with opioids, the initial dose of Oxicodona/Naloxona Teva may be higher.
The maximum daily dose is 160 mg of hydrochloride oxicodona and 80 mg of hydrochloride naloxona. If you need a higher dose, your doctor may prescribe more hydrochloride oxicodona without hydrochloride naloxona. However, the maximum daily dose of hydrochloride oxicodona should not exceed 400 mg.
The beneficial effect of hydrochloride naloxona on intestinal activity may be affected if the dose of hydrochloride oxicodona is increased without increasing the dose of hydrochloride naloxona.
If you substitute Oxicodona/Naloxona Teva for another opioid analgesic, it is likely that your intestinal function will worsen.
If you experience pain between two doses of Oxicodona/Naloxona Teva, you may need to take an additional rapid-acting analgesic. Oxicodona/Naloxona Teva is not a treatment for this case. Discuss it with your doctor.
If you think the effect of Oxicodona/Naloxona Teva is too strong or too weak, consult your doctor or pharmacist.
For pain treatment
Older patients
Generally, no dose adjustment is necessary in older patients with normal kidney and/or liver function.
Liver or kidney disorder
If you have a kidney disorder or mild liver disorder, your doctor will prescribe Oxicodona/Naloxona Teva with special caution. If you have a moderate or severe liver disorder, you should not take Oxicodona/Naloxona Teva (see also section 2 “Do not take Oxicodona/Naloxona Teva” and “Warnings and Precautions”).
Children and adolescents under 18 years
Oxicodona/Naloxona Teva has not been studied in children and adolescents under 18 years. Its safety and efficacy have not been demonstrated in children and adolescents. Therefore, the use of Oxicodona/Naloxona Teva in children and adolescents under 18 years is not recommended.
Administration form
The tablets are for oral use. You should take Oxicodona Naloxona Teva with sufficient liquid (half a glass of water). The tablet can be divided into equal doses, but it should not be chewed or crushed. You can take the tablet with or without food.
Take Oxicodona/Naloxona Teva every 12 hours, following a fixed schedule (e.g., at 8 am and 8 pm).
Duration of use
Generally, you should not take Oxicodona/Naloxona Teva for longer than necessary. If you receive Oxicodona/Naloxona Teva for a long time, your doctor should regularly check that you still need Oxicodona/Naloxona Teva.
If you take more Oxicodona/Naloxona Teva than you should
If you have taken more Oxicodona/Naloxona Teva than prescribed, you should inform your doctor immediately. Consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20 indicating the medication and the amount used. It is recommended to bring the packaging and the medication leaflet to the healthcare professional.
A overdose can cause:
• pupil constriction
• slow and shallow breathing (respiratory depression)
• drowsiness that can lead to loss of consciousness
• low muscle tone (hypotonia)
• reduced heart rate, and
• decreased blood pressure.
In severe cases, it can cause loss of consciousness (coma), fluid accumulation in the lungs, and circulatory collapse, which can be fatal in some cases.
You should avoid situations that require a high level of alertness, such as driving.
If you forgot to take Oxicodona/Naloxona Teva
If you forget to take Oxicodona/Naloxona Teva or if you take a dose lower than prescribed, you may not feel the effect.
If you forget to take a dose, follow these instructions:
• If 8 hours or more have passed since the next scheduled dose: take the missed prolonged-release tablet of Oxicodona/Naloxona Teva immediately, and continue with the regular schedule.
• If less than 8 hours have passed since the next scheduled dose: take the missed prolonged-release tablet of Oxicodona/Naloxona Teva. Wait 8 hours before taking the next prolonged-release tablet. Try to recover the original schedule (e.g., 8 am and 8 pm).
• Do not take Oxicodona/Naloxona Teva more than once in an 8-hour period.
Do not take a double dose to compensate for missed doses.
If you interrupt the treatment with Oxicodona/Naloxona Teva
Do not interrupt the treatment with Oxicodona/Naloxona Teva without consulting your doctor.
If you no longer need to continue treatment, you should gradually reduce the daily dose, after discussing it with your doctor. This will help you avoid withdrawal symptoms, such as restlessness, sweating, and muscle pain.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Important side effects to be aware of, and what to do if you experience them:
If you already experience any of the following important side effects, consult your nearest doctor immediately.
Slow and shallow breathing (respiratory depression) is the main danger of opioid overdose. It occurs mainly in elderly and weakened patients. Opioids can also cause a severe drop in blood pressure in susceptible patients.
The following side effects were observed in patients treated for pain:
Frequent(may affect up to 1 in 10 people)
Less frequent(may affect up to 1 in 100 people)
- Seizures (especially in people with epilepsy or predisposition to seizures)
Rare(may affect up to 1 in 1,000 people)
Unknown frequency(frequency cannot be estimated from available data)
It is known that the active principle hydrochloride of oxicodone, if not combined with hydrochloride of naloxone, has the following side effects, different from those mentioned:
Oxicodone can cause respiratory problems (respiratory depression), pupil constriction, muscle cramps of the bronchial and smooth muscles, and depression of the cough reflex.
Frequent(may affect up to 1 in 10 people)
Poorly frequent(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Unknown frequency(frequency cannot be estimated from available data)
The following side effects have been observed:
Very frequent(may affect more than 1 in 10 people)
Frequent(may affect up to 1 in 10 people)
Poorly frequent(may affect up to 1 in 100 people)
Unknown frequency(frequency cannot be estimated from available data)
Communication of side effects
If you experienceany type of side effect, consult your doctor, pharmacist, or nurse, even if it is apossibleside effect that does not appear in this prospectus.You can also communicate them directlythrough the Spanish System of Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Do not use this medication after the expiration date that appears on the box, label, and blister after “CAD”.The expiration date is the last day of the month indicated.
Blister: Do not store above 25°C.
Bottles: Do not store above 30°C.
Medications should not be disposed of through drains or trash. Deposit the containers and medications you no longer need at the SIGRE collection point of the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medications you no longer need. This will help protect the environment.
Composition ofOxicodona/Naloxona Teva
The active ingredients are hydrochloride of oxicodona and hydrochloride of naloxona.
Each prolonged-release tablet contains 30 mg of hydrochloride of oxicodona (equivalent to 27 mg of oxicodona) and 15 mg of hydrochloride of naloxona (as 16.35 mg of hydrochloride of naloxona dihydrate equivalent to 13.5 mg of naloxona).
The other components are:
Tablet core
Polivinyl acetate, povidone, sodium lauryl sulfate, anhydrous colloidal silica, microcrystalline cellulose, and magnesium stearate.
Tablet coating
Polivinyl alcohol, titanium dioxide (E171), macrogol, talc, and yellow iron oxide (E172).
Appearance of the product and contents of the package
Prolonged-release yellow, oblong, biconvex, scored on both sides, with a length of 12.2 mm, a width of 5.7 mm, and a height of 3.3 – 4.3 mm.
The tablet can be divided into equal doses.
Oxicodona/Naloxona Teva is available in: child-resistant blister pack of 10, 14, 20, 28, 30, 50, 56, 60, 90, 98, and 100 prolonged-release tablets; perforated unit-dose child-resistant blister pack of 10x1, 14x1, 20x1, 28x1, 30x1, 50x1, 56x1, 60x1, 90x1, 98x1, and 100x1 prolonged-release tablets; or a child-resistant bottle containing 50, 100, 200, or 250 prolonged-release tablets.
Not all package sizes may be marketed.
Marketing authorization holder and responsible manufacturer
Marketing authorization holder
Teva Pharma, S.L.U.
C/ Anabel Segura nº 11, Edificio Albatros B, 1st floor
Alcobendas 28108 (Madrid)
Spain
Responsible manufacturer
Develco Pharma GmbH
Grienmatt 27, Schopfheim 79650
Germany
or
PLIVA Hrvatska d.o.o. (PLIVA Croatia Ltd.)
Prilaz baruna Filipovica 25,
10000 Zagreb
Croatia
This medicine is authorized in the member states of the European Economic Area with the following names:
Bulgaria:?????????/????????????10 mg/5 mg, 20 mg/10 mg??????????????????????????????
Croatia: Oksikodon/nalokson Pliva 5 mg/2.5 mg; 10 mg/5 mg; 20 mg/10 mg; 40 mg/20 mg tablete s produljenim oslobadanjem
Finland: Oxycodone/Naloxone ratiopharm 5/2,5, 10/5, 20/10, 30/15, 40/20mg depottabletti
Germany: Oxycodon comp.-AbZ 5 mg/2,5 mg, 10 mg/5 mg, 20 mg/10 mg, 30 mg/15 mg,
40 mg/20 mg Retardtabletten
Italy: Noxidol 5mg/2,5mg, 10mg/5mg, 20mg/10mg, 30mg/15mg, 40mg/20mg
Poland: Oxyduo
Spain: Oxicodona/Naloxona Teva 5/2.5, 10/5, 20/10, 30/15, 40/20mg comprimidos de liberación prolongada EFG
Sweden: Oxycodone/Naloxone Teva
Last review date of this leaflet: April 2025
Other sources of information
Detailed information about thismedicine is available on the website of the Spanish Agency of Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es/)
You can access detailed and updated information about this medicine by scanning the QR code included in the carton with your smartphone. You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/81727/P_81727.html
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.